Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral drug shows promise against deadly lassa fever in west africa trial

NCT ID NCT07419373

Disease control Sponsor: Arisan Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests a new oral antiviral drug, ARN-75039, for treating Lassa fever, a serious viral illness common in West Africa. About 135 hospitalized adults will receive either a high or low dose of the new drug or the standard IV treatment, ribavirin, for 10 days. The goal is to see if the new pill is safe and can reduce the virus faster than the current treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 135 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following criteria to be eligible for enrollment: * Age ≥ 18 years * Hospitalized with clinical disease consistent with Lassa fever * Positive plasma Lassa virus RT-PCR at screening * Requires hospitalization for Lassa fever per local clinical guidelines * Able to provide written informed consent, or consent provided by a legally authorized representative. Exclusion Criteria: Participants will be excluded if they meet any of the following criteria: * Pregnant (confirmed by positive urine pregnancy test in women of childbearing potential) * Receipt of specific drug therapy for Lassa fever (e.g., ribavirin, direct antivirals, or host-directed therapies including corticosteroids) within 15 days before enrollment * Prior vaccination against Lassa fever * History of severe gastrointestinal disease * History of chronic generalized pruritus * History of severe chronic liver disease * History of severe cardiac disorder Sex and Reproductive Criteria * Women of childbearing potential must have a negative pregnancy test at screening * Breastfeeding is not permitted during the treatment period and early follow-up * Participants must agree to comply with protocol-defined contraception requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lassa fever are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Communicable Diseases, Emerging Lassa fever Neglected Diseases viral hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lassa fever

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Abubakar Tafawa Balewa University Teaching Hospital

    Bauchi, Nigeria

  • Arisan Therapeutics

    Carlsbad, California, 92008, United States

  • Federal Medical Centre, Owo

    Owo, Ondo State, Nigeria

  • Irrua Specialist Teaching Hospital

    Irrua, 310115, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.